Literature DB >> 7059977

Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,2-dihydro-3-[(N-methylanilino)methyl]-pyrido[3,4-b]pyrazin-7-ylcarbamate (NSC 181928).

G P Wheeler, B J Bowdon, J A Werline, D J Adamson, C G Temple.   

Abstract

Ethyl 5-amino-1,2-dihydro-3-[N-methylanilino)methyl]pyrido[3,4-b]pyrazin-7-ylcarbamate (NSC 181928) is reported to be active against several experimental neoplasms. The experimental data obtained in the present study indicate that it causes the accumulation of cells at mitosis with both cultured cells and ascites cancer cells in vivo. This effect was observed with L1210, P388, colon cancer 26, colon cancer 38, and H.Ep. 2 cells in culture and with L1210 cells and P388 cells in mice. The agent was also active in vitro and in vivo against a line of leukemia P388 cells that are resistant to vincristine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7059977

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147.

Authors:  W R Waud; S D Harrison; C G Temple; D P Griswold
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  CI-980 in advanced melanoma and hormone refractory prostate cancer.

Authors:  C W Ryan; K L Shulman; J M Richards; J W Kugler; J A Sosman; R H Ansari; E E Vokes; N J Vogelzang
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

Review 3.  Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).

Authors:  M Smith; P T Ho
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.

Authors:  R P Whitehead; J M Unger; L E Flaherty; J R Eckardt; S A Taylor; M S Didolkar; W Samlowski; V K Sondak
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

5.  A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors.

Authors:  N T Sklarin; C D Lathia; L Benson; W R Grove; S Thomas; J Roca; A I Einzig; P H Wiernik
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

6.  Optimum scheduling during combination chemotherapy of murine leukemia. Additional examples of schedule-dependent synergism between S-phase-specific antimetabolites and agents inducing mitotic or pre-mitotic (G2) arrest.

Authors:  F M Sirotnak; F A Schmid; C Temple; J A Montgomery
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

7.  Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas.

Authors:  S R Patel; M A Burgess; N E Papadopolous; G Sidhu; R Gray; C Plager; J Jenkins; R S Benjamin
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

8.  Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15.

Authors:  M García-Rocha; M D García-Gravalos; J Avila
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.